Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34785111

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur J Cancer
Publication date
2022 Jan
First author
Stutterheim J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Stutterheim J
      type
      Author
    2. name
      de Lorenzo P
      type
      Author
    3. name
      van der Sluis IM
      type
      Author
    4. name
      Alten J
      type
      Author
    5. name
      Ancliffe P
      type
      Author
    6. name
      Attarbaschi A
      type
      Author
    7. name
      Aversa L
      type
      Author
    8. name
      Boer JM
      type
      Author
    9. name
      Biondi A
      type
      Author
    10. name
      Brethon B
      type
      Author
    11. name
      Diaz P
      type
      Author
    12. name
      Cazzaniga G
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Stutterheim J
      type
      Author
    2. name
      de Lorenzo P
      type
      Author
    3. name
      van der Sluis IM
      type
      Author
    4. name
      Alten J
      type
      Author
    5. name
      Ancliffe P
      type
      Author
    6. name
      Attarbaschi A
      type
      Author
    7. name
      Aversa L
      type
      Author
    8. name
      Boer JM
      type
      Author
    9. name
      Biondi A
      type
      Author
    10. name
      Brethon B
      type
      Author
    11. name
      Diaz P
      type
      Author
    12. name
      Cazzaniga G
      type
      Author
    bibliography ids
    1. nci-bib-d1a6f7cec5b216029a36b9a4
    book metadata
    content sha256
    394be267cb1c5c5dc2b4e3c85f4d42593464260bc07e50a319ca0972f5177181
    document type
    citation
    dois
    1. 10.1016/j.ejca.2021.10.004
    electronic publication date
    display
    2021 Nov 13
    precision
    day
    year
    2021
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:34785111
    immutable id
    pubmed:34785111@394be267cb1c5c5dc2b4e3c85f4d42593464260bc07e50a319ca0972f5177181
    journal
    abbreviation
    Eur J Cancer
    issn electronic
    1879-0852
    issn print
    0959-8049
    issue
    Source null
    name
    European journal of cancer (Oxford, England : 1990)
    nlm unique id
    9005373
    pages
    72-79
    volume
    160
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      34785111
      provenance
      batch id
      3f4d1914d2afe41e9e70
      provider
      NCBI PubMed ESummary
      record sha256
      c46fbfbb1691d422c4ca32848f0cf91577bc638049304a1f9253ce692afeeeb8
      response sha256
      0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
      retrieved at
      2026-09-09T23:48:06.522634+00:00
      publication date
      display
      2022 Jan
      precision
      month
      year
      2022
      publication types
      1. Journal Article
      2. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/34785111/
      title
      Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.

      Preserved source evidence · Not medical advice